Disease Landscape and Forecast Insights

How Does Cost versus Dosing Impact Prescriber Preferences and Payer Policy? The prevalence of age-related macular degeneration (AMD) is increasing with the aging population in China. Therapies…

Physician Perspectives and the Impact of Payer Policy on Prescribing An estimated 121 million people are living with chronic kidney disease (CKD) in China. This high prevalence can be…

Physician and Payer Attitudes and the Impact of the Aging Population Aging is considered a new healthcare challenge globally, and Alzheimer’s disease (AD) is one of the most debilitating…

Physician and Payer Perspectives as Smoking and Pollution Perils Point to Sharply Increasing COPD Incidence Chronic obstructive pulmonary disease (COPD) has become a leading case of mortality…

Physician and Payer Perspectives on Prescribing and Patient Access China has long wrestled with an increasing prevalence in respiratory diseases that has accompanied its economic growth and…

The increase in patient awareness and the longer life expectancies are driving the growth of the Chinese diabetes market. There is potentially great opportunity for multinational pharmaceutical…

China has one of the most rapidly growing pharmaceutical markets in the world, as well as a vast, rapidly expanding prevalent population of Hepatitis C (HCV) patients. The key driver of the Chinese…

Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications and a host of laboratory and patient demographic variables help define…

Warfarin has been the mainstay of anticoagulation therapy for the past several decades, but difficulties associated with its use and the clinical management of patients have prompted the…

Chronic myeloid leukemia (CML) in China presents a huge challenge for healthcare providers but is a considerable opportunity for drug manufacturers. The launch of Novartis’s Glivec (imatinib), an…

Gastric cancer (GC) is a major public health burden in China and is the third leading cause of cancer-related deaths in the country. Although chemotherapy is the mainstay of treatment, prescribing…

The Chinese market for hepatocellular carcinoma (HCC) therapies represents an increasingly lucrative space for many pharmaceutical companies. Although the high prices demanded by targeted brands…